These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15964332)

  • 1. Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial.
    Gotti E; Perico N; Gaspari F; Cattaneo D; Lesti MD; Ruggenenti P; Segoloni G; Salvadori M; Rigotti P; Valente U; Donati D; Sandrini S; Federico S; Sparacino V; Mourad G; Bosmans JL; Dimitrov BD; Iordache BE; Remuzzi G
    Transplant Proc; 2005 Jun; 37(5):2037-40. PubMed ID: 15964332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial.
    Perico N; Ruggenenti P; Gotti E; Gaspari F; Cattaneo D; Valente U; Salvadori M; Segoloni G; Donati D; Sandrini S; Ganeva M; Dimitrov BD; Remuzzi G;
    Kidney Int; 2004 Mar; 65(3):1084-90. PubMed ID: 14871429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
    Arns W; Zantvoort F; Abendroth D; Seiter H; Scheuermann EH; Albert U; Stahl R; Fornara P; Fricke L; Neumayer HH; Nagel E; Michel U; Ulbricht B
    Transplant Proc; 2005 Apr; 37(3):1612-5. PubMed ID: 15866687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation.
    Aumente MD; Arizón JM; Segura J; López A; Albornoz R; Cárdenas M; Segura C
    Transplant Proc; 2005 Nov; 37(9):4014-7. PubMed ID: 16386613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P; Asberg A; Guldseth H; Bremer S; Akhlaghi F; Reubsaet JL; Pfeffer P; Hartmann A; Midtvedt K
    Transplantation; 2008 Jan; 85(2):179-84. PubMed ID: 18212621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: the receiver operating characteristic curve analysis.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Ostrowska J; Gralak B; Majchrzak J
    Transplant Proc; 2006; 38(1):86-9. PubMed ID: 16504671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
    Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
    Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of early cyclosporine levels in pediatric kidney transplantation.
    Matas AJ; Gillingham KJ; Chavers BM; Nevins T; Kashtan C; Mauer SM; Payne WD; Gruessner R; Najarian JS
    Clin Transplant; 1996 Dec; 10(6 Pt 1):482-6. PubMed ID: 8996767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of postdose cyclosporine monitoring in living renal transplant recipients.
    Thomas R; Minz M; Singh B; Heer M; Kashyap R
    Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study.
    Barbari AG; Masri MA; Stephan AG; El Ghoul B; Rizk S; Mourad N; Kamel GS; Kilani HE; Karam AS
    Exp Clin Transplant; 2006 Jun; 4(1):400-5. PubMed ID: 16827634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new strategy for monitoring levels of cyclosporin A in the blood of patients after kidney transplantation].
    Halacová M; Jedlicková B; Průsa R
    Ceska Slov Farm; 2003 Nov; 52(6):267-71. PubMed ID: 14661365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between Neoral 2 hours post-dose levels and histologic findings on surveillance biopsies.
    Barama A; Sepandj F; Gough J; McKenna R
    Transplant Proc; 2004 Mar; 36(2 Suppl):465S-467S. PubMed ID: 15041389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying cyclosporine blood levels associated with the prevention of renal transplant rejection: a single-center, randomized prospective study.
    Britto ZM; David-Neto E; Lemos FC; Pereira LM; Castro MC; Fonseca JA; Alves CF; Nahas WC; Ianhez LE; David-Neto E
    Transplant Proc; 2004 Nov; 36(9):2649-55. PubMed ID: 15621114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.